ALCON N overview

Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025. Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect Deborah Di Sanzo as a new Board member. An innovative business leader with more than thirty years of experience in...

Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025. Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect Deborah Di Sanzo as a new Board member. An innovative business leader with more than thirty years...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the introduction of Clareon ® PanOptix ® Pro intraocular lens (IOL) for cataract patients in the U.S. PanOptix Pro leverages proprietary ENLIGHTEN ® NXT Optical technology which delivers the highest reported light utilization of any trifocal IOL—and the lowest light scatter. 1-3,6-10,§,** These enhancements also provide more uninterrupted light distribution from distance to...

Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies to treat eye diseases. Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal endothelial disease during the...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies to treat eye diseases. Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal endothelial disease during the second half of...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Vivity ® , the most widely implanted 9 extended depth of focus (EDOF) intraocular lens (IOL), is now available on Alcon’s most advanced lens material—Clareon ® . 1 Clareon Vivity ® received CE Mark and will commence commercial rollout in Europe from early Q2 2025. "Cataracts are the most common cause of vision loss globally 10 , and in Germany alone, 10 million patients...

Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Vivity ® , the most widely implanted 9 extended depth of focus (EDOF) intraocular lens (IOL), is now available on Alcon’s most advanced lens material—Clareon ® . 1 Clareon Vivity ® received CE Mark and will commence commercial rollout in Europe from early Q2 2025. "Cataracts are the most common cause of vision loss globally 10 , and in Germany alone, 10...